



ASX ANNOUNCEMENT

Key Executive Appointments to Support Upcoming Clinical Studies

Perth, Australia, 31 March 2021: Neuroscientific Biopharmaceuticals Limited (ASX: NSB) (NeuroScientific or the Company) is pleased to announce the appointment of Dougal Thring as Vice President of Clinical Development and Dr Alexandra Heaton as Director of Operations to support the upcoming clinical programs in Glaucoma and Neurodegenerative Diseases.

Dougal brings over 12 years of experience in leading all aspects of clinical development of Phase I and Phase II clinical studies for numerous domestic and international biotechnology companies. Prior to joining Neuroscientific Biopharmaceuticals, Dougal worked as a Head of Clinical Solutions at Linear Clinical Research Ltd, a leading early-phase Australian contract research organisation. While at Linear he was responsible for identifying the best clinical strategy for the initiation and completion of early-stage clinical programs for their clients. Dougal's qualifications include a Bachelor of Medical and Pharmaceutical Biotechnology (1st Class Honours) from the University of South Australia and Masters of Pharmaceutical Medicine from the University of New South Wales.

Dr Alexandra Heaton holds a PhD in Neuroscience (University of Western Australia) with her research work focused on anti-oxidative, anti-inflammatory and anti-apoptotic effects of dietary supplementation in the brain in addition to enhancing neuroplasticity, synaptogenesis and neural signalling. Prior to joining Neuroscientific Biopharmaceuticals, Alexandra had the role of US Client Engagement with Linear Clinical Research Ltd, focusing on attracting partnerships with US Biotechnology and Pharmaceutical companies.

Matthew Liddelow, CEO and Managing Director, commented "NeuroScientific is pleased to have secured both Dougal and Alexandra in key executive management positions at an important stage of development in the Company's R&D program. Dougal brings a wealth of clinical research experience to the Company, having worked closely with many global pharmaceutical companies during the conduct of their early-phase clinical studies, while employed at one of Australia's leading clinical research organisations. Alexandra's appointment provides the Company with the necessary skills and knowledge to support our preclinical and clinical R&D activities as the Company transitions into the clinical stage of development."

About Neuroscientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

END

Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Nonexecutive Chairman
bl@neuroscientific.com
+61 412 281 780